IL4 and atopic asthma: The recombinant human IL-4 variant, pitrakinra (Aerovant) competitively inhibits the IL-4Ra receptor complex to interfere with the actions of both IL-4 and IL-13 and initial clinical trials indicated that such an approach may prove beneficial in patients with atopic asthma (Walsh, 2012).